Novo Nordisk A/S (NYSE:NVO) Expected to Post Quarterly Sales of $6.03 Billion

Wall Street brokerages predict that Novo Nordisk A/S (NYSE:NVOGet Rating) will post $6.03 billion in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Novo Nordisk A/S’s earnings. The highest sales estimate is $6.05 billion and the lowest is $6.02 billion. Novo Nordisk A/S reported sales of $5.35 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 12.7%. The firm is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Novo Nordisk A/S will report full year sales of $24.44 billion for the current financial year, with estimates ranging from $24.11 billion to $24.75 billion. For the next financial year, analysts expect that the company will post sales of $27.25 billion, with estimates ranging from $26.86 billion to $27.45 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVOGet Rating) last released its earnings results on Friday, April 29th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.09. The company had revenue of $6.34 billion during the quarter, compared to the consensus estimate of $5.82 billion. Novo Nordisk A/S had a return on equity of 72.67% and a net margin of 33.16%.

NVO has been the topic of a number of research reports. Stifel Nicolaus initiated coverage on shares of Novo Nordisk A/S in a report on Monday, February 28th. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft increased their target price on shares of Novo Nordisk A/S from 850.00 to 900.00 in a report on Wednesday, May 4th. Berenberg Bank increased their target price on shares of Novo Nordisk A/S from 585.00 to 780.00 and gave the stock a “hold” rating in a report on Tuesday, April 19th. Bryan, Garnier & Co upgraded shares of Novo Nordisk A/S from a “sell” rating to a “neutral” rating in a report on Thursday, May 5th. Finally, Barclays increased their target price on shares of Novo Nordisk A/S from 850.00 to 875.00 and gave the stock an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and a consensus price target of $563.50.

NYSE:NVO traded up $1.69 on Wednesday, reaching $106.04. 1,484,426 shares of the company’s stock were exchanged, compared to its average volume of 1,515,718. Novo Nordisk A/S has a 52-week low of $78.71 and a 52-week high of $122.16. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.36. The business has a fifty day moving average of $111.15 and a 200-day moving average of $107.77.

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 5th. Investors of record on Monday, March 28th were paid a dividend of $0.741 per share. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. This represents a yield of 1.1%. The ex-dividend date was Friday, March 25th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 44.05%.

Large investors have recently made changes to their positions in the stock. Mathes Company Inc. purchased a new position in Novo Nordisk A/S during the 4th quarter worth $1,930,000. Ahrens Investment Partners LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $25,000. Farmers & Merchants Investments Inc. purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $26,000. Cornerstone Advisory LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $28,000. Finally, Bell Investment Advisors Inc purchased a new stake in Novo Nordisk A/S during the third quarter worth about $28,000.

About Novo Nordisk A/S (Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

See Also

Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.